Genentech, 1 DNA Way, South San Francisco, California 94080, USA.
Nature. 2017 Jan 18;541(7637):321-330. doi: 10.1038/nature21349.
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
免疫疗法在多种癌症中被证明是一种有效的治疗方法。但尽管针对免疫调节剂 CTLA4 和 PD-L1/PD-1 的抗体在临床上取得了成功，但只有一部分人表现出持久的反应，这表明需要更广泛地了解癌症免疫。免疫受一系列复杂的肿瘤、宿主和环境因素的影响，这些因素决定了抗癌反应的强度和时机。临床研究开始将这些因素定义为免疫谱，可以预测免疫治疗的反应。在癌症免疫循环的背景下，这些因素共同代表了个体的固有免疫状态或“癌症免疫设定点”。
